GlaxoSmithKline Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
GLAXO
Pharmaceuticals
Share Price NSE
₹2596.90
▲
19.00 (0.74%)
Share Price BSE
₹2600.10
▲
29.00 (1.13%)
Track GlaxoSmithKline Pharmaceuticals share price live with TickJournal's free stock screener.
Analyze GlaxoSmithKline Pharmaceuticals share price history trends and compare 52-week high low
levels.
Calculate GLAXO stock fair value using fundamental analysis and view live share price charts.
Determine GlaxoSmithKline Pharmaceuticals share intrinsic value and compare it with current GLAXO share price.
Record your GlaxoSmithKline Pharmaceuticals trades in TickJournal's free trading journal and track your portfolio performance.
GlaxoSmithKline Pharmaceuticals Market Cap
₹43,950.70 Cr.
GLAXO P/E Ratio (TTM)
44.25
EPS (TTM)
₹54.76
Dividend Yield
2.02%
Debt to Equity
0.01
GLAXO 52 Week High
₹3466.20
GlaxoSmithKline Pharmaceuticals 52 Week Low
₹2272.60
Operating Margin
34.00%
Profit Margin
25.91%
GLAXO Revenue (TTM)
₹1,015.00
EBITDA
₹374.00
Net Income
₹263.00
Total Assets
₹4,108.00
Total Equity
₹1,951.00
GlaxoSmithKline Pharmaceuticals Share Price History - Stock Screener Chart
Screen GLAXO historical share price movements with interactive charts. Analyze price trends and patterns.
GlaxoSmithKline Pharmaceuticals Company Profile - Fundamental Screener
Screen GlaxoSmithKline Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GLAXO shares.
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Renu S Karnad
ISIN
INE159A01016
Website
https://www.gsk-india.com
GlaxoSmithKline Pharmaceuticals Balance Sheet Screener
Screen GLAXO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 |
| Current Assets | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 | 2,174 |
| Fixed Assets | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 | 210 |
| Liabilities | ||||||||||
| Total Liabilities | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 |
| Current Liabilities | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 | 292 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 | 2,183 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 | 85 |
| Reserves & Surplus | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 | 2,099 |
GlaxoSmithKline Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen GlaxoSmithKline Pharmaceuticals income statement and profit fundamentals.
Analyze GLAXO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for GlaxoSmithKline Pharmaceuticals share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,015 | 849 | 1,016 | 1,091 | 962 | 850 | 1,050 | 985 | 826 | 815 | 985 | 833 | 2,132 | 776 | 939 |
| Expenses | 641 | 554 | 644 | 670 | 673 | 584 | 689 | 658 | 618 | 618 | 668 | 751 | 634 | 596 | 660 |
| EBITDA | 374 | 295 | 372 | 421 | 290 | 266 | 361 | 327 | 208 | 198 | 318 | 83 | 1,497 | 180 | 279 |
| Operating Profit % | 34.00% | 31.00% | 34.00% | 36.00% | 28.00% | 28.00% | 32.00% | 31.00% | 22.00% | 19.00% | 30.00% | 7.00% | 22.00% | 20.00% | 28.00% |
| Depreciation | 15 | 16 | 17 | 20 | 18 | 16 | 17 | 19 | 17 | 16 | 18 | 17 | 15 | 16 | 16 |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit Before Tax | 359 | 279 | 354 | 400 | 271 | 249 | 344 | 308 | 190 | 181 | 299 | 65 | 1,482 | 163 | 262 |
| Tax | 96 | 74 | 97 | 104 | 76 | 67 | 91 | 78 | 57 | 49 | 82 | 20 | 263 | 44 | 69 |
| Net Profit | 263 | 205 | 258 | 296 | 195 | 182 | 253 | 230 | 133 | 132 | 218 | 46 | 1,219 | 119 | 193 |
| EPS | 15.52 | 12.10 | 15.07 | 16.54 | 11.37 | 10.76 | 14.67 | 13.57 | 7.41 | 7.04 | 12.84 | 9.89 | 71.96 | 7.04 | 11.42 |
GlaxoSmithKline Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLAXO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 | 139 |
| Investing Activities | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 | 499 |
| Financing Activities | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 | -638 |
| Net Cash Flow | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 | 0 |
GlaxoSmithKline Pharmaceuticals Shareholding Pattern Screener
See GlaxoSmithKline Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check GlaxoSmithKline Pharmaceuticals promoter holding and ownership changes for GLAXO on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 4.52% | 4.89% | 4.80% | 4.64% | 3.48% | 4.02% | 4.36% | 4.50% |
| DII Holding | 7.79% | 7.70% | 7.75% | 7.70% | 7.90% | 7.50% | 7.34% | 7.30% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.60% | 10.32% | 10.34% | 10.36% | 11.27% | 11.15% | 10.97% | 10.96% |
| Other Holding | 2.09% | 2.09% | 2.11% | 2.30% | 2.35% | 2.33% | 2.33% | 2.23% |
| Shareholder Count | 121,885 | 123,629 | 122,904 | 122,460 | 118,994 | 118,515 | 119,228 | 119,625 |
GlaxoSmithKline Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check GlaxoSmithKline Pharmaceuticals dividend history with payout and yield data.
View GlaxoSmithKline Pharmaceuticals dividend details including ex-dates and amounts for GLAXO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹54.00 | 2.08% |
| 2024-March | ₹32.00 | 1.11% |
| 2023-March | ₹32.00 | 1.64% |
| 2022-March | ₹90.00 | 7.05% |
| 2021-March | ₹30.00 | 1.80% |
| 2020-March | ₹40.00 | 2.78% |
| 2019-March | ₹20.00 | 1.59% |
| 2018-March | ₹35.00 | 2.70% |
| 2017-March | ₹30.00 | 2.87% |
GlaxoSmithKline Pharmaceuticals Stock Index Membership
See which indices include GlaxoSmithKline Pharmaceuticals stock.
Check GLAXO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
GlaxoSmithKline Pharmaceuticals Market Events Screener - Corporate Actions
Get GlaxoSmithKline Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check GlaxoSmithKline Pharmaceuticals stock events that may affect GLAXO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Bonus | 1:1 | -0.11% | ||
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 1.10% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -3.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -3.21% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 21.34% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 42.00 /share | 19.92% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | -7.08% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.77% |
| 2024-11-07 | 2024-11-07 | Dividend | ₹ 12.00 /share | -0.47% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | 0.52% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | 32.30% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 32.00 /share | 28.12% |
| 2023-06-30 | 2023-06-30 | Dividend | ₹ 32.00 /share | 11.53% |
| 2022-07-26 | 2022-07-26 | Annual General Meeting | NA | 0.04% |
| 2022-07-07 | 2022-07-08 | Dividend | ₹ 30.00 /share | 0.84% |
GlaxoSmithKline Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLAXO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
GlaxoSmithKline Pharmaceuticals Company Announcements - News Screener
Screen GLAXO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-17 | Financial Results For Quarter & Nine Months December 2025 | View |
| 2026-02-17 | Board Meeting Outcome for Outcome Of Meeting | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-06 | Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025. | View |
| 2026-01-01 | Disclosure Under Regulation 30 | View |
| 2025-12-31 | Disclosure Under Regulation 30 | View |
| 2025-12-31 | Volume Movement Letter | View |
| 2025-12-31 | Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd | - |
| 2025-12-23 | Closure of Trading Window | View |
| 2025-12-22 | Disclosure Under Regulation 30 | View |
| 2025-12-18 | Disclosure Under Regulation 30 | View |
| 2025-12-12 | Disclosure Under Regulation 30 | View |
| 2025-11-19 | Disclosure Under Regulation 30 | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |